Metformin and lung cancer risk of patients with type 2 diabetes mellitus: A meta-analysis

Abstract

Objectives: The objective of this study was to evaluate the association between metformin therapy and the incidence of gastric cancer (GC) in patients with type 2 diabetes mellitus (T2DM). Methods: We systemically searched the following databases for studies published between the databases' dates of inception and Nov. 2016: PubMed, Embase, the Cochrane Library, the Web of Science, and the China National Knowledge Infrastructure (CNKI). Hazard ratios (HR) and corresponding 95% confidence intervals (CIs) for the association between metformin therapy and the incidence of GC in patients with T2DM were the outcome measures assessed in this study. STATA 12.0 (Stata Corporation, College Station, Texas, USA) was used to conduct the statistical analysis. Results: A total of seven cohort studies including 591,077 patients met all the criteria for inclusion in the analysis. Our data showed that metformin therapy was associated with a significantly lower incidence of GC in patients with T2DM than other types of therapy (HR=0.763, 95% CI: 0.642~0.905). Subgroup analysis showed that patients living in Taiwan benefitted more from metformin therapy than patients living in any other region, as metformin significantly decreased the risk of GC in patients living in Taiwan but did not significantly decrease the risk of GC in patients living in other regions (HR=0.514, 95% CI: 0.384-0.688). The results of the present analysis support the idea that metformin facilitates reductions in the risk of T2DM-related GC. Conclusions: The risk of GC among patients with T2DM is lower in patients receiving metformin therapy than in patients not receiving metformin therapy.

Metformin restores crizotinib sensitivity in crizotinib-resistant human lung cancer cells through inhibition of IGF1-R signaling pathway

“…In recent years, a number of retrospective epidemiological and pre-clinical studies have supported the use of metformin as an adjuvant in the chemotherapy for cancer treatment [21]. In lung cancer patients with diabetes, meta-analysis showed that the use of metformin improved survival [22]. A retrospective study from our group showed that in advanced NSCLC patients with type 2 diabetes, metformin together with EGFR-TKI resulted in longer PFS and OS [23].…”

Environment Dictates Dependence on Mitochondrial Complex I for NAD+ and Aspartate Production and Determines Cancer Cell Sensitivity to Metformin

“…Because of its widespread use, an abundance of epidemiological data is available for how metformin might influence other disease states. Retrospective studies have found that taking metformin is associated with improved cancer outcomes, with reductions in cancer incidence and with decreased cancer mortality observed across many tumor types (Evans et al, 2005; Gandini et al, 2014; He et al, 2012; Lee et al, 2012; Zhu et al, 2015). These findings have resulted in studies examining the anti-tumorigenic properties of metformin and other biguanides on cancer cell lines and in mouse models of cancer, as well as clinical trials exploring potential roles for metformin in cancer therapy.…”

Impact of metformin use on the outcomes of newly diagnosed diffuse large B‐cell lymphoma and follicular lymphoma

“…Type 2 DM is considered as a risk factor for many types of cancer (Shlomai et al, 2016;Cignarelli et al, 2018;Sacerdote & Ricceri, 2018). Multiple studies have suggested that metformin use was associated with lower incidences of various solid tumours such as pancreatic, colorectal, gastric, lung and breast cancer (Gandini et al, 2014;Wang et al, 2014;Zhu et al, 2015;Shlomai et al, 2016;Kobiela et al, 2018;Li et al, 2018b). There is also accumulating evidence that supports an association of metformin use with improved outcome of several types of solid tumours (Chu et al, 2018;Hu et al, 2018;Kobiela et al, 2018;Li et al, 2018b;Tang et al, 2018;Xin et al, 2018).…”